MCID: RTN003
MIFTS: 48

Retinal Ischemia malady

Categories: Eye diseases

Aliases & Classifications for Retinal Ischemia

Aliases & Descriptions for Retinal Ischemia:

Name: Retinal Ischemia 38 12 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:12510
ICD10 33 H35.82
ICD9CM 35 362.84
SNOMED-CT 64 193427006 26468004
UMLS 69 C0162291

Summaries for Retinal Ischemia

MalaCards based summary : Retinal Ischemia is related to exudative vitreoretinopathy 3 and exudative vitreoretinopathy 4. An important gene associated with Retinal Ischemia is HIF1A (Hypoxia Inducible Factor 1 Alpha Subunit), and among its related pathways/superpathways are PEDF Induced Signaling and PAK Pathway. The drugs Bevacizumab and Dorzolamide have been mentioned in the context of this disorder. Affiliated tissues include bone, endothelial and eye, and related phenotypes are Increased Nanog expression and cellular

Related Diseases for Retinal Ischemia

Diseases related to Retinal Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 64)
id Related Disease Score Top Affiliating Genes
1 exudative vitreoretinopathy 3 10.8
2 exudative vitreoretinopathy 4 10.8
3 transient cerebral ischemia 10.8
4 mini stroke 10.8
5 exudative vitreoretinopathy 1 10.8
6 exudative vitreoretinopathy 2, x-linked 10.8
7 ischemia 10.8
8 retinitis 10.8
9 neuronitis 10.1
10 rectum adenoma 10.1 CASP3 HIF1A VEGFA
11 isolated anterior cervical hypertrichosis 10.1 HIF1A VEGFA
12 cleft palate cardiac defect ectrodactyly 10.1 HIF1A SETD2 VEGFA
13 sarcomatoid renal cell carcinoma 10.1 HIF1A SETD2 VEGFA
14 endotheliitis 10.1
15 endocervicitis 10.1 BAX HIF1A VEGFA
16 central nervous system leiomyosarcoma 10.1 CXCL12 HIF1A VEGFA
17 thanatophoric dysplasia, type ii 10.0 BAX CASP3 HIF1A
18 degenerative disc disease 10.0 TNF VEGFA
19 twin-to-twin transfusion syndrome 10.0 BAX TNF
20 ovarian brenner tumor 10.0 HIF1A SETD2 TNF VEGFA
21 oppositional defiant disorder 10.0 CXCL12 HIF1A TNF VEGFA
22 pyloric antrum cancer 10.0 BAX PCNA VEGFA
23 neurological manifestations of pompe disease 9.9 CAT SOD1
24 uvula cancer 9.9 BAX CAT VEGFA
25 vogt-koyanagi-harada disease 9.9 CASP3 NFKB1 TNF VEGFA
26 cutis laxa, autosomal recessive, type ib 9.9 CASP3 CXCL12 TNF VEGFA
27 baritosis 9.9 CAT SOD1 TNF
28 ectodermal dysplasia bartalos type 9.9 SOD1 TNF VEGFA
29 choroiditis 9.8
30 retinal vein occlusion 9.8
31 nail disorder, nonsyndromic congenital, 3, 9.8 BAX CASP3 HIF1A TNF VEGFA
32 neurofibromatosis 9.8
33 neurofibromatosis, type 1 9.8
34 mucopolysaccharidosis is 9.8 CASP2 CASP3 SETD2 SOD1
35 substance-induced psychosis 9.7 CASP3 SOD1 TNF VEGFA
36 muscular dystrophy-dystroglycanopathy , type b, 2 9.7 BAX CASP3 HIF1A PCNA VEGFA
37 ocular hypertension 9.7
38 central retinal artery occlusion 9.7
39 neovascular glaucoma 9.7
40 hypoxia 9.7
41 cerebritis 9.7
42 temporal arteritis 9.7
43 cataract 9.7
44 retinal artery occlusion 9.7
45 histiocytoid hemangioma 9.7 KNG1 SOD1 VEGFA
46 myocardial infarction 9.6 CASP3 CXCL12 HIF1A KNG1 TNF VEGFA
47 carotid stenosis 9.5
48 eales disease 9.5
49 wallerian degeneration 9.5
50 melanoma 9.5

Comorbidity relations with Retinal Ischemia via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Retinal Ischemia:



Diseases related to Retinal Ischemia

Symptoms & Phenotypes for Retinal Ischemia

GenomeRNAi Phenotypes related to Retinal Ischemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Nanog expression GR00371-A-1 9.9 VEGFA CASP2 PCNA SETD2
2 Increased Nanog expression GR00371-A-2 9.9 SETD2 VEGFA
3 Increased Nanog expression GR00371-A-4 9.9 SETD2 VEGFA
4 Increased Nanog expression GR00371-A-5 9.9 VEGFA CASP2 SETD2
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 HIF1A NFKB1 PCNA SOD1 TNF BAX
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 HIF1A NFKB1 PCNA SOD1 TNF BAX
7 Increased cell death HMECs cells GR00103-A-0 9.72 CASP2 CASP3 CAT HIF1A PCNA
8 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.65 CASP2 CASP3 CAT PCNA TNF
9 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.35 BAX HIF1A NFKB1 PCNA SOD1

MGI Mouse Phenotypes related to Retinal Ischemia:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 BAX CASP2 CASP3 CAT CXCL12 HIF1A
2 hematopoietic system MP:0005397 10.3 BAX CASP2 CASP3 CXCL12 HIF1A HSPB1
3 growth/size/body region MP:0005378 10.28 BAX CASP3 HIF1A HSPB1 KNG1 NFKB1
4 immune system MP:0005387 10.24 BAX CASP2 CASP3 CXCL12 HIF1A HSPB1
5 mortality/aging MP:0010768 10.23 NFKB1 PCNA SETD2 SOD1 TNF VEGFA
6 homeostasis/metabolism MP:0005376 10.21 NFKB1 SETD2 SOD1 TNF VEGFA BAX
7 endocrine/exocrine gland MP:0005379 10.2 TNF VEGFA CASP3 HIF1A NFKB1 PCNA
8 nervous system MP:0003631 10.07 BAX CASP2 CASP3 CXCL12 HIF1A NFKB1
9 craniofacial MP:0005382 10.03 CASP3 HIF1A NFKB1 SETD2 TNF VEGFA
10 muscle MP:0005369 10.03 BAX CASP3 CXCL12 HIF1A NFKB1 SOD1
11 liver/biliary system MP:0005370 9.95 CXCL12 HIF1A NFKB1 SOD1 TNF VEGFA
12 neoplasm MP:0002006 9.88 BAX CAT HIF1A SOD1 TNF VEGFA
13 reproductive system MP:0005389 9.86 SOD1 TNF VEGFA BAX CASP2 CASP3
14 no phenotypic analysis MP:0003012 9.8 CASP3 CXCL12 HSPB1 PCNA TNF VEGFA
15 respiratory system MP:0005388 9.63 BAX CASP3 HIF1A NFKB1 TNF VEGFA
16 skeleton MP:0005390 9.56 BAX CASP3 HIF1A NFKB1 SETD2 SOD1
17 vision/eye MP:0005391 9.17 VEGFA BAX CASP3 HIF1A SETD2 SOD1

Drugs & Therapeutics for Retinal Ischemia

Drugs for Retinal Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
2
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
3
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2 347396-82-1 459903
4
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
5
Timolol Approved Phase 4 26839-75-8 33624 5478
6
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
7
Dipyridamole Approved Phase 4 58-32-2 3108
8
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
9
Choline Approved, Nutraceutical Phase 4 62-49-7 305
10 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
11 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Anticholesteremic Agents Phase 4
13 Antimetabolites Phase 4
14 Calcium, Dietary Phase 4
15 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
16 Hypolipidemic Agents Phase 4
17 Lipid Regulating Agents Phase 4
18 Rosuvastatin Calcium Phase 4 147098-20-2
19 Antihypertensive Agents Phase 4,Phase 3,Phase 1,Phase 2
20 Carbonic Anhydrase Inhibitors Phase 4
21 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
23 Cytidine Diphosphate Choline Phase 4
24 Nootropic Agents Phase 4
25 Adrenergic Agents Phase 4,Phase 1,Phase 2
26 Adrenergic Antagonists Phase 4,Phase 1,Phase 2
27 Adrenergic beta-Antagonists Phase 4,Phase 1,Phase 2
28 Anti-Arrhythmia Agents Phase 4,Phase 1,Phase 2
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
30 Analgesics Phase 4,Phase 3
31 Analgesics, Non-Narcotic Phase 4,Phase 3
32 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3
33 Antipyretics Phase 4,Phase 3
34 Antirheumatic Agents Phase 4,Phase 3
35 Cyclooxygenase Inhibitors Phase 4,Phase 3
36 Fibrinolytic Agents Phase 4,Phase 3
37 Phosphodiesterase Inhibitors Phase 4,Phase 2
38 Platelet Aggregation Inhibitors Phase 4,Phase 3
39 Vasodilator Agents Phase 4,Phase 2,Phase 1
40 Antibodies Phase 4
41 Immunoglobulins Phase 4
42 Phosphodiesterase 5 Inhibitors Phase 4
43 Sildenafil Citrate Phase 4 171599-83-0
44 Vardenafil Dihydrochloride Phase 4
45
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
46
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
47
Irbesartan Approved, Investigational Phase 3 138402-11-6 3749
48
Triamcinolone Approved, Vet_approved Phase 3,Phase 2 124-94-7 31307
49
Vorapaxar Approved Phase 3 618385-01-6
50
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594

Interventional clinical trials:

(show top 50) (show all 114)
id Name Status NCT ID Phase
1 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4
2 The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques Unknown status NCT01773512 Phase 4
3 Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial Completed NCT02299336 Phase 4
4 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Completed NCT01710839 Phase 4
5 Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Completed NCT01175070 Phase 4
6 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4
7 Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4
8 The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial) Completed NCT00957190 Phase 4
9 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4
10 Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. Completed NCT01997489 Phase 4
11 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Recruiting NCT02432547 Phase 4
12 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT03046693 Phase 4
13 Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion Recruiting NCT02478515 Phase 4
14 Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa Recruiting NCT02554747 Phase 4
15 PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT00867815 Phase 4
16 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Active, not recruiting NCT02503540 Phase 4
17 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial) Active, not recruiting NCT02368756 Phase 4
18 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Not yet recruiting NCT02522897 Phase 4
19 Ranibizumab and the Risk of Arterial Thromboembolic Events Terminated NCT01319188 Phase 4
20 Outcomes of Steroid and Oxygen Therapy Versus Placebo Therapy in Non-arteritic Anterior Ischemic Optic Neuropathy Unknown status NCT02439866 Phase 3
21 Central Vein Occlusion Study (CVOS) Completed NCT00000131 Phase 3
22 Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion Completed NCT02033031 Phase 3
23 Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia Completed NCT00152698 Phase 3
24 Combined Triple Procedure in Retinal Vein Occlusion (RVO) Completed NCT00805064 Phase 3
25 Intravitreal Bevacizumab for Diabetic Retinopathy Completed NCT00600262 Phase 2, Phase 3
26 Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) Completed NCT00617123 Phase 3
27 Combined Triple Therapy in Diabetic Retinopathy (DRP) Completed NCT00806169 Phase 3
28 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial Recruiting NCT00991029 Phase 3
29 Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT02341560 Phase 2, Phase 3
30 Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study) Recruiting NCT02376881 Phase 3
31 The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT Active, not recruiting NCT02157350 Phase 3
32 Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Not yet recruiting NCT02947867 Phase 2, Phase 3
33 A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Not yet recruiting NCT02215330 Phase 2, Phase 3
34 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3
35 Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion Terminated NCT00732927 Phase 3
36 Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy Unknown status NCT01518842 Phase 1, Phase 2
37 Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients Unknown status NCT02405741 Phase 2
38 Comparison of Two Laser Therapy Methods for PDR Unknown status NCT01232179 Phase 2
39 Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants Unknown status NCT00910234 Phase 1, Phase 2
40 Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease Completed NCT00841373 Phase 1, Phase 2
41 Traumatic Optic Neuropathy Treatment Trial (TONTT) Completed NCT01783847 Phase 1, Phase 2
42 A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow Completed NCT00569621 Phase 2
43 Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion Completed NCT00815360 Phase 2
44 Effects of Moxaverine and Placebo on Ocular Blood Flow Completed NCT00709423 Phase 2
45 Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study Completed NCT01238471 Phase 1, Phase 2
46 Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. Recruiting NCT02222610 Phase 2
47 Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment. Recruiting NCT02957760 Phase 2
48 Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy. Recruiting NCT02151695 Phase 2
49 Fluoxetine for Visual Recovery After Ischemic Stroke Recruiting NCT02737930 Phase 2
50 Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) Active, not recruiting NCT01552408 Phase 1, Phase 2

Search NIH Clinical Center for Retinal Ischemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Retinal Ischemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Retinal Ischemia:
Bone marrow-derived stem cells for retinal diseases
Embryonic/Adult Cultured Cells Related to Retinal Ischemia:
Bone marrow-derived mononuclear cells (family) PMIDs: 23049424 21225138 19347139 23000646

Genetic Tests for Retinal Ischemia

Anatomical Context for Retinal Ischemia

MalaCards organs/tissues related to Retinal Ischemia:

39
Bone, Endothelial, Eye, Retina, Bone Marrow, Neutrophil, Spleen

Publications for Retinal Ischemia

Articles related to Retinal Ischemia:

(show top 50) (show all 288)
id Title Authors Year
1
Myeloid differentiation protein 2-dependent mechanisms in retinal ischemia-reperfusion injury. ( 28063877 )
2017
2
Involvement of microRNA-181a and Bim in a rat model of retinal ischemia-reperfusion injury. ( 26949607 )
2016
3
Cellular Stress Response and Immune Signaling in Retinal Ischemia-Reperfusion Injury. ( 27822213 )
2016
4
Hypoxic-Preconditioned Bone Marrow Stem Cell Medium Significantly Improves Outcome After Retinal Ischemia in Rats. ( 27367588 )
2016
5
Protective effect of etanercept, an inhibitor of tumor necrosis factor-I+, in a rat model of retinal ischemia. ( 27259948 )
2016
6
Postconditioning with inhaled hydrogen promotes survival of retinal ganglion cells in a rat model of retinal ischemia/reperfusion injury. ( 26705611 )
2016
7
Neuroprotective impact of prothymosin alpha-derived hexapeptide against retinal ischemia-reperfusion. ( 26779836 )
2016
8
Lower Hemoglobin Concentration Is Associated with Retinal Ischemia and the Severity of Diabetic Retinopathy in Type 2 Diabetes. ( 27200379 )
2016
9
Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase. ( 27617027 )
2016
10
Cryopreserved Mesenchymal Stromal Cells Maintain Potency in a Retinal Ischemia/Reperfusion Injury Model: Toward an off-the-shelf Therapy. ( 27212469 )
2016
11
Inhibiting Matrix Metalloproteinase 3 Ameliorates Neuronal Loss in the Ganglion Cell Layer of Rats in Retinal Ischemia/Reperfusion. ( 26830289 )
2016
12
Methane attenuates retinal ischemia/reperfusion injury via anti-oxidative and anti-apoptotic pathways. ( 27208496 )
2016
13
Peripheral retinal ischemia in a young Indian woman with neurofibromatosis type 1. ( 26949362 )
2016
14
A Mouse Model of Retinal Ischemia-Reperfusion Injury Through Elevation of Intraocular Pressure. ( 27501124 )
2016
15
Astaxanthin Protects Against Retinal Damage: Evidence from In Vivo and In Vitro Retinal Ischemia and Reperfusion Models. ( 27158842 )
2016
16
C1q propagates microglial activation and neurodegeneration in the visual axis following retinal ischemia/reperfusion injury. ( 27008854 )
2016
17
Functional and Structural Evaluation of Sildenafil in a Rat Model of Acute Retinal Ischemia/Reperfusion Injury. ( 27421045 )
2016
18
Refractory acute angle-closure glaucoma with retinal ischemia: January consultation #1. ( 26948794 )
2016
19
Pre-treatment with vinpocetine protects against retinal ischemia. ( 27899287 )
2016
20
The protective effect of prophylactic ozone administration against retinal ischemia-reperfusion injury. ( 27028056 )
2016
21
Utility of optical coherence tomography in the evaluation of monocular visual loss related to retinal ischemia. ( 26765759 )
2016
22
Cannabinoid receptors and TRPA1 on neuroprotection in a model of retinal ischemia. ( 27876485 )
2016
23
Calpain-1 and calpain-2 play opposite roles in retinal ganglion cell degeneration induced by retinal ischemia/reperfusion injury. ( 27185592 )
2016
24
Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemia. ( 26238242 )
2015
25
Peripheral Retinal Ischemia, Neovascularization, and Choroidal Infarction in Wyburn-Mason Syndrome. ( 25906291 )
2015
26
Hydrogen-rich saline reduces cell death through inhibition of DNA oxidative stress and overactivation of poly (ADP-ribose) polymerase-1 in retinal ischemia-reperfusion injury. ( 25954991 )
2015
27
Neuroprotective effect of water-dispersible hesperetin in retinal ischemia reperfusion injury. ( 26407617 )
2015
28
Regulatory networks in retinal ischemia-reperfusion injury. ( 25902940 )
2015
29
Comparison of pre-treatment and post-treatment use of selenium in retinal ischemia reperfusion injury. ( 25938038 )
2015
30
Modeling transient retinal ischemia in mouse by ligation of pterygopalatine artery. ( 26526209 )
2015
31
Structural and functional changes in retinal vasculature induced by retinal ischemia-reperfusion in rats. ( 25728136 )
2015
32
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion. ( 26689280 )
2015
33
Chitosan oligosaccharides prevented retinal ischemia and reperfusion injury via reduced oxidative stress and inflammation in rats. ( 25479043 )
2015
34
A novel imidazopyridine derivative, X22, prevents the retinal ischemia-reperfusion injury via inhibition of MAPKs. ( 25907396 )
2015
35
Effects of curcumin on interleukin-23 and interleukin-17 expression in rat retina after retinal ischemia-reperfusion injury. ( 26464670 )
2015
36
VINPOCETINE MODULATES METABOLIC ACTIVITY AND FUNCTION DURING RETINAL ISCHEMIA. ( 25696811 )
2015
37
Activation of autophagy and paraptosis in retinal ganglion cells after retinal ischemia and reperfusion injury in rats. ( 25574219 )
2015
38
Angiogenic and Inflammatory Vitreous Biomarkers Associated With Increasing Levels of Retinal Ischemia. ( 26447988 )
2015
39
Peripheral retinal ischemia following posttraumatic ocular hypertension in the setting of sickle cell trait. ( 25763551 )
2015
40
Prediction of Retinal Ischemia in Branch Retinal Vein Occlusion: Spectral-Domain Optical Coherence Tomography Study. ( 26465891 )
2015
41
Upregulation of Homer1a Promoted Retinal Ganglion Cell Survival After Retinal Ischemia and Reperfusion via Interacting with Erk Pathway. ( 25924704 )
2015
42
Nerve growth factor protects retinal ganglion cells against injury induced by retinal ischemia-reperfusion in rats. ( 25707536 )
2015
43
The protective effects of dexmedetomidine against apoptosis in retinal ischemia/reperfusion injury in rats. ( 24517497 )
2014
44
Effect of the renin inhibitor aliskiren against retinal ischemia-reperfusion injury. ( 24709336 )
2014
45
Effect of retinal ischemia on the non-image forming visual system. ( 25238585 )
2014
46
Down-regulation of GRP78 enhances apoptosis via CHOP pathway in retinal ischemia-reperfusion injury. ( 24880098 )
2014
47
Delayed administration of bone marrow mesenchymal stem cell conditioned medium significantly improves outcome after retinal ischemia in rats. ( 24699381 )
2014
48
Transplantation with retinal progenitor cells repairs visual function in rats with retinal ischemia-reperfusion injury. ( 24076256 )
2014
49
Retinal ischemia/reperfusion injury is mediated by Toll-like receptor 4 activation of NLRP3 inflammasomes. ( 25097240 )
2014
50
Protective effects of the neuropeptides PACAP, substance P and the somatostatin analogue octreotide in retinal ischemia: a metabolomic analysis. ( 24514073 )
2014

Variations for Retinal Ischemia

Expression for Retinal Ischemia

Search GEO for disease gene expression data for Retinal Ischemia.

Pathways for Retinal Ischemia

Pathways related to Retinal Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 BAX CASP2 CASP3 CXCL12 NFKB1 TNF
2
Show member pathways
13.25 BAX CASP2 CASP3 CXCL12 NFKB1 TNF
3
Show member pathways
12.86 BAX CASP3 NFKB1 PCNA TNF
4
Show member pathways
12.85 CASP2 CASP3 CXCL12 NFKB1 TNF
5
Show member pathways
12.84 BAX CASP2 CASP3 NFKB1 TNF
6
Show member pathways
12.76 BAX CASP3 HIF1A NFKB1 VEGFA
7
Show member pathways
12.69 BAX CASP2 CASP3 HSPB1 NFKB1 TNF
8 12.65 CASP2 CASP3 HSPB1 NFKB1 TNF
9
Show member pathways
12.57 CASP2 CASP3 NFKB1 TNF VEGFA
10
Show member pathways
12.55 HSPB1 NFKB1 TNF VEGFA
11 12.51 BAX CASP3 CXCL12 HIF1A NFKB1 VEGFA
12
Show member pathways
12.46 CASP2 CASP3 NFKB1 TNF
13 12.39 BAX NFKB1 PCNA TNF
14
Show member pathways
12.33 BAX CASP3 NFKB1 PCNA
15
Show member pathways
12.29 CAT NFKB1 SOD1 TNF
16 12.26 CASP3 HIF1A TNF VEGFA
17
Show member pathways
12.23 CASP3 HIF1A NFKB1 VEGFA
18
Show member pathways
12.21 BAX CASP2 CASP3 HIF1A
19 12.17 BAX CASP3 NFKB1 TNF
20
Show member pathways
12.15 BAX CASP2 CASP3 HSPB1 TNF
21
Show member pathways
12.07 CASP2 CASP3 NFKB1 TNF
22 12.07 BAX CASP3 NFKB1 VEGFA
23
Show member pathways
12.06 BAX CAT NFKB1 SOD1
24 12.05 NFKB1 TNF VEGFA
25 11.98 BAX CASP3 NFKB1 TNF VEGFA
26 11.97 BAX NFKB1 TNF
27 11.95 BAX CAT NFKB1
28 11.95 HIF1A TNF VEGFA
29 11.93 CASP3 HIF1A NFKB1 TNF VEGFA
30 11.92 CASP3 NFKB1 TNF
31 11.88 HIF1A NFKB1 VEGFA
32 11.86 CXCL12 NFKB1 TNF
33
Show member pathways
11.84 HIF1A HSPB1 VEGFA
34 11.83 CXCL12 TNF VEGFA
35 11.81 CASP3 HSPB1 NFKB1 TNF
36 11.74 CASP3 NFKB1 TNF
37
Show member pathways
11.7 BAX CASP2 CASP3 NFKB1
38
Show member pathways
11.68 BAX CASP3 CXCL12 NFKB1
39 11.66 CXCL12 HIF1A VEGFA
40
Show member pathways
11.64 NFKB1 TNF VEGFA
41
Show member pathways
11.64 BAX CASP2 CASP3 NFKB1 TNF
42 11.56 CASP3 NFKB1 TNF
44 11.52 CASP3 HIF1A NFKB1 SOD1
45 11.47 KNG1 NFKB1 TNF
46 11.46 NFKB1 TNF VEGFA
47 11.42 BAX NFKB1 TNF
48
Show member pathways
11.41 BAX CASP3 CAT SOD1 TNF
49
Show member pathways
11.37 CAT NFKB1 SOD1
50 11.31 BAX HIF1A VEGFA

GO Terms for Retinal Ischemia

Cellular components related to Retinal Ischemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 CAT CXCL12 HSPB1 KNG1 SOD1 TNF
2 axon cytoplasm GO:1904115 8.8 HIF1A HSPB1 SOD1

Biological processes related to Retinal Ischemia according to GeneCards Suite gene sharing:

(show all 42)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron apoptotic process GO:0043524 9.85 BAX HIF1A SOD1
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 CAT NFKB1 TNF
3 response to oxidative stress GO:0006979 9.84 CAT PCNA SOD1
4 platelet degranulation GO:0002576 9.83 KNG1 SOD1 VEGFA
5 response to virus GO:0009615 9.82 CXCL12 HSPB1 TNF
6 positive regulation of angiogenesis GO:0045766 9.81 HIF1A HSPB1 VEGFA
7 kidney development GO:0001822 9.79 BAX CAT VEGFA
8 response to estradiol GO:0032355 9.79 CASP3 CAT PCNA
9 response to organic substance GO:0010033 9.78 CASP3 SOD1 TNF
10 positive regulation of endothelial cell proliferation GO:0001938 9.73 CXCL12 HIF1A VEGFA
11 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.71 BAX CASP2 PCNA
12 response to hydrogen peroxide GO:0042542 9.7 CASP3 CAT SOD1
13 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.69 HSPB1 VEGFA
14 positive regulation of blood vessel endothelial cell migration GO:0043536 9.68 HSPB1 VEGFA
15 positive regulation of neuroblast proliferation GO:0002052 9.68 HIF1A VEGFA
16 B cell homeostasis GO:0001782 9.68 BAX CASP3
17 camera-type eye morphogenesis GO:0048593 9.67 HIF1A VEGFA
18 positive regulation of cell adhesion GO:0045785 9.67 CXCL12 TNF VEGFA
19 muscle cell cellular homeostasis GO:0046716 9.66 HIF1A SOD1
20 negative regulation of apoptotic signaling pathway GO:2001234 9.66 BAX HSPB1
21 positive regulation of chemokine production GO:0032722 9.65 HIF1A TNF
22 response to reactive oxygen species GO:0000302 9.65 CAT SOD1
23 positive regulation of neuron apoptotic process GO:0043525 9.65 BAX CASP2 CASP3
24 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.63 HIF1A VEGFA
25 induction of positive chemotaxis GO:0050930 9.63 CXCL12 VEGFA
26 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.62 HSPB1 TNF
27 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.62 BAX CASP2 CASP3 TNF
28 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.61 BAX CASP2 TNF
29 myeloid cell homeostasis GO:0002262 9.6 BAX SOD1
30 activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c GO:0008635 9.59 BAX CASP3
31 response to salt stress GO:0009651 9.58 BAX TNF
32 cellular response to nicotine GO:0071316 9.58 NFKB1 TNF
33 ovarian follicle development GO:0001541 9.58 BAX SOD1 VEGFA
34 ectopic germ cell programmed cell death GO:0035234 9.57 BAX CASP2
35 apoptotic signaling pathway GO:0097190 9.56 BAX CASP2 CASP3 TNF
36 positive regulation of axon extension involved in axon guidance GO:0048842 9.55 CXCL12 VEGFA
37 response to hypoxia GO:0001666 9.55 CASP3 CAT CXCL12 HIF1A VEGFA
38 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.54 BAX CASP2 CASP3
39 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.51 HSPB1 VEGFA
40 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.46 HIF1A VEGFA
41 positive regulation of apoptotic process GO:0043065 9.43 BAX CASP2 CASP3 KNG1 SOD1 TNF
42 negative regulation of apoptotic process GO:0043066 9.23 CASP2 CASP3 CAT HIF1A HSPB1 NFKB1

Molecular functions related to Retinal Ischemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.63 BAX CAT HSPB1 NFKB1 SOD1 VEGFA
2 enzyme binding GO:0019899 9.35 CASP2 CAT HIF1A PCNA SOD1
3 cysteine-type endopeptidase activity involved in execution phase of apoptosis GO:0097200 9.32 CASP2 CASP3
4 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.26 CASP2 CASP3
5 identical protein binding GO:0042802 9.23 BAX CASP2 HSPB1 NFKB1 PCNA SOD1

Sources for Retinal Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....